Tagged Articles

bevacizumab 9 articles

Cancer drug Avastin with chemo granted priority review for treatment of ovarian cancer

The Food and Drug Administration (FDA) has granted Priority Review status for the cancer drug Avastin (bevacizumab) plus chemotherapy for the treatment of women with recurrent platinum-resistant ovarian cancer. Avastin is already approved to treat specific types of colorectal, lung, kidney, and brain cancers. Avastin was also granted priority review for the treatment of cervical cancer. The Priority Review status is based on data from the Phase 3 AURELIA trial, a multicenter, randomized, open-label study in 361 women with platinum-resistant recurrent epithelial ovarian, primary peritoneal or fallopian tube cancer who have received no more than two anticancer regimens prior to ... Read More

Experimental vaccine shows promise against most aggressive brain tumors

More than 90 percent of patients with a highly reoccurring type of brain cancer treated with an experimental vaccine were alive six months after undergoing surgery, a far better prognosis than patients who followed standard treatment, according to a study published in the journal Neuro-Oncology and accompanied by an editorial highlighting the importance of the trial.  “The grim prognosis is exactly why new research is important,” says Orin Bloch, MD, a neurosurgeon at Northwestern Memorial Hospital and lead author of the study. The tumor, known as glioblastoma multiforme, or GBM, is the same type of tumor that took the life ... Read More

FDA finds second counterfeit cancer drug

The Food and Drug Administration (FDA) has found a second counterfeit cancer drug that has been illegally distributed to medical practices in the United States. Last month, the FDA obtained counterfeit versions of Genetech’s Avastin that contained salt, starch, and a variety of chemicals, but none of the active ingredient bevacizumab that fights cancer. The latest drug, a counterfeit version of Roche’s Altuzan, with the same ingredient, bevacizumab, was also found not to have the active ingredient. Even if the Altuzan obtained was not counterfeit, that drug is not approved by the FDA for use in the United States. (It is ... Read More

Counterfeit cancer drug traced back to distributors in Egypt

Counterfeit vials of the cancer drug Avastin that were found circulating in Europe and the United States earlier this month contain salt, starch and a variety of chemicals, but none of the active ingredient bevacizumab that fights cancer. Avastin is an injectable medicine made by Swiss drug maker Roche. It is administered to patients at clinics, hospitals and doctors’ offices. It is used to treat various forms of cancer including colon, kidney, brain and lung cancers. Avastin made headlines recently when the Food and Drug Administration (FDA) pulled the drug’s breast cancer indication because it was not proven safe or ... Read More

FDA removes breast cancer indication from Avastin

After months of debate, the Food and Drug Administration (FDA) has ordered that the breast cancer indication for the drug Avastin be removed because it is not proven safe and effective to treat the disease. Breast cancer survivors petitioned an FDA advisory panel earlier this year to keep the drug as a breast cancer treatment. “I never thought that in the United States I would have to beg for a drug that is keeping me and many others alive,” a breast cancer survivor told the panel during a hearing last summer. But the pleas of breast cancer victims fell on deaf ... Read More

Breast cancer indication for Avastin still a ‘no’

Breast cancer survivors pleaded to a Food and Drug Administration (FDA) panel of experts earlier this week to keep the breast cancer indication for the drug Avastin (bevacizumab). Avastin is used for the treatment of colon, kidney, brain and lung cancers. Late last year, the FDA voted to remove the breast cancer indication from the drug because it did not prove safe and effective in studies among patients with breast cancer. The FDA’s recommendation is based on the results of four clinical studies of Avastin in women with breast cancer. The FDA found that the data from those studies indicated ... Read More

Avastin shows promising results in ovarian cancer studies

The cancer drug Avastin (bevacizumab) may have had a setback recently when the Food and Drug Administration (FDA) pulled the drug’s breast cancer indication, but it is showing promising results in ovarian cancer studies. Roche Holding AG announced this week that Avastin helped women suffering from ovarian cancer live longer without their disease getting worse. The phase III study, which will be published later this year, found that women who were treated with Avastin in combination with chemotherapy, followed by the continued use of Avastin alone, lived longer without progression of their disease, compared to women who received chemotherapy only. ... Read More

FDA removes breast cancer indication for Avastin

The Food and Drug Administration (FDA) has ruled to remove the breast cancer indication for Avastin (bevacizumab) because the drug has not proved safe and effective in studies among patients with breast cancer. The drug itself is not being removed from the market, and the FDA’s action will not immediately impact its use in treating breast cancer. The action also will not affect the approvals already in place for the drug in the treatment of colon, kidney, brain and lung cancers. The FDA recommendation is based on the results of four clinical studies of Avastin in women with breast cancer. ... Read More

Study: Avastin can extend life of ovarian cancer patients

A widely used cancer drug can help women with ovarian cancer live longer, according to a new European study. Roche’s Avastin (bevacizumab) is already used for the treatment of various cancers including bowel, breast and lung cancers. A study of about 1,800 women presented during the European Society for Medical Oncology (ESMO) congress showed that the drug extended progression-free survival in women with advanced ovarian cancer to 14.1 months when taken in addition to chemotherapy versus 10.3 months with chemotherapy alone. Avastin works by inhibiting vascular endothelial growth factor (VEGF), which is thought to play a role in disease progression. ... Read More